Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.
Adjuvant everolimus did not improve disease-free survival in patients with DLBCL and confirmed complete response after 1 year of rituximab treatment.
Continuing letrozole therapy after 5 years of aromatase inhibitor therapy did not worsen quality-of-life measures in patients with HR-positive breast cancer.
A new analytical tool called topographic single-cell sequencing can reveal a direct genomic lineage between in situ and invasive tumor subpopulations, which may help decipher how and why some DCIS become invasive.
Bladder cancer patients with tumors smaller than 1 cm could be classified as “very-low-risk,” with recurrences that could arise after the 5-year surveillance period.
Treatment of previously untreated follicular lymphoma with atezolizumab combined with obinutuzumab and bendamustine was associated with widespread adverse events and a treatment-related death, according to an interim analysis of a phase Ib/II cohort study.
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer
Neoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.
ASCO clinical practice guidelines recommend resection followed by treatment with gemcitabine and capecitabine as the standard of care; however, neoadjuvant therapy is also considered an appropriate alternative.
A 56-year-old Caucasian woman presented to her primary care physician with a 3-month history of intermittent bright red rectal blood with defecation. At her initial visit, a digital rectal examination, anoscopy, and a pelvic examination with DNA testing for high-risk HPV were performed; all results were negative. She was referred for a colonoscopy, which revealed an abnormal area with a 3 × 4–cm mass in the rectum at a distance of 10 cm from the anal verge.
With increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Here, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Here, in Part 1, we will provide an overview of the epidemiology of primary CNS lymphoma, followed by a discussion of the diagnostic and staging evaluation. We will also review the current prognostication systems for primary CNS lymphoma.
Last month we asked our readers: If you were to start your career again, would you still choose oncology, would you pick a different specialty, or would you perhaps not choose a career in medicine at all? Here are the results.
This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.
The FDA has expanded the approval of the PARP inhibitor olaparib (Lynparza) to include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.